Page last updated: 2024-08-24

valsartan and Heart Failure, Systolic

valsartan has been researched along with Heart Failure, Systolic in 18 studies

Research

Studies (18)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	12 (66.67)	24.3611
2020's	6 (33.33)	2.80

Authors

Authors	Studies
Davis, LE; Pogge, EK	1
Hori, M; Imamura, T; Kinugawa, K	1
Arnaud, H; Bouali, Y; Donal, E; Galli, E; Laurin, C; Oger, E; Paven, E	1
Aili, A; Bate, B; Chen, P; Dan, S; Guo, J; Han, Z; Hou, D; Hu, G; Kuransi, A; Nay, X; Qiqike, B; Xia, B; Xie, J; Zhu, M	1
Brunetti, ND; Correale, M; Di Biase, M; Ferraretti, A; Formica, ES; Iacoviello, M; Merolla, G; Monaco, I; Padovano, G; Tozzi, V; Tricarico, L	1
Alonso Salinas, GL; Bascompte Claret, R; Cordero Pereda, D; Del Prado Díaz, S; Gayán Ordás, J; Jiménez-Blanco Bravo, M; Morillas Climent, H; Seller Moya, J; Valle, A; Zamorano Gómez, JL	1
Davis, LE; Lu, BN	1
De Marco, A; Fragasso, G; Gemma, M; Margonato, A; Pinto, G; Silipigni, C; Spoladore, R; Tondi, L	1
Adie, S; Bitar, A; Dorsch, M; Hanigan, S; Koelling, T; Pogue, K	1
Desai, AS; Gong, J; Lefkowitz, MP; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, J; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR	1
Einecke, D	2
Frantz, S; Hundertmark, M	1
Widimský, J	1
Farmakis, D; Filippatos, G; Lekakis, J; Parissis, J	1
Lillyblad, MP	1
Jacob, MS; Sabe, MA; Taylor, DO	1
Starling, RC	1

Reviews

3 review(s) available for valsartan and Heart Failure, Systolic

Article	Year
[Heart failure: new insights and developments]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:49 Topics: Acute Disease; Aminobutyrates; Biphenyl Compounds; Cardiac Resynchronization Therapy; Combined Modality Therapy; Drug Combinations; Heart Failure, Diastolic; Heart Failure, Systolic; Humans; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Relaxin; Spironolactone; Survival Rate; Tetrazoles; Valsartan	2014
[The new drug is much more effective than ACE inhibitors in chronic heart failure]. Vnitrni lekarstvi, 2015, Volume: 61, Issue:2 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure, Systolic; Hospitalization; Humans; Male; Middle Aged; Tetrazoles; Valsartan	2015
Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:11 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure, Systolic; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan	2015

Trials

2 trial(s) available for valsartan and Heart Failure, Systolic

Article	Year
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact European journal of heart failure, 2013, Volume: 15, Issue:9 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure, Systolic; Hospitalization; Humans; Morbidity; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Single-Blind Method; Survival Rate; Tetrazoles; Valsartan	2013
A new class of drugs for systolic heart failure: The PARADIGM-HF study. Cleveland Clinic journal of medicine, 2015, Volume: 82, Issue:10 Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Cough; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure, Systolic; Hospitalization; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Neprilysin; Renal Insufficiency; Tetrazoles; Valsartan	2015

Article

Year

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

European journal of heart failure, 2013, Volume: 15, Issue:9

Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure, Systolic; Hospitalization; Humans; Morbidity; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Single-Blind Method; Survival Rate; Tetrazoles; Valsartan

2013

A new class of drugs for systolic heart failure: The PARADIGM-HF study.

Cleveland Clinic journal of medicine, 2015, Volume: 82, Issue:10

Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Cough; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure, Systolic; Hospitalization; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Neprilysin; Renal Insufficiency; Tetrazoles; Valsartan

2015

Other Studies

13 other study(ies) available for valsartan and Heart Failure, Systolic

Article	Year
Outcome Benefits Seen With 1 Year of Optimized Sacubitril/Valsartan for the Treatment of Systolic Heart Failure Managed by Pharmacists in a Cardiology Practice. The Annals of pharmacotherapy, 2022, Volume: 56, Issue:5 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cardiology; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Pharmacists; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left	2022
Optimal Therapeutic Strategy Using Sacubitril/Valsartan in a Patient with Systolic Heart Failure and Chronic Kidney Disease - An Initial Case Report in Japan. Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:17 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Japan; Male; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan	2021
Impact of sacubitril/valsartan on systolic heart failure: Right heart location and clustering analysis. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2022, Volume: 31, Issue:2 Topics: Aged; Aminobutyrates; Biphenyl Compounds; Cluster Analysis; Drug Combinations; Female; Heart Failure; Heart Failure, Systolic; Humans; Male; Middle Aged; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left	2022
Sacubitril/Valsartan Cannot Improve Cardiac Function Compared with Valsartan in Patients Suffering Nonvalvular Atrial Fibrillation without Systolic Heart Failure. International heart journal, 2023, Volume: 64, Issue:6 Topics: Atrial Fibrillation; Biomarkers; Heart Failure; Heart Failure, Systolic; Humans; Stroke Volume; Tetrazoles; Valsartan	2023
Predictors of clinical improvement with sacubitril/valsartan in a real world population with chronic heart failure. Journal of cardiovascular medicine (Hagerstown, Md.), 2021, 06-01, Volume: 22, Issue:6 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; CA-125 Antigen; Drug Combinations; Female; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Male; Middle Aged; Mortality; Outcome Assessment, Health Care; Prognosis; ROC Curve; Treatment Outcome; Valsartan	2021
Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry). Journal of cardiovascular pharmacology, 2021, 11-01, Volume: 78, Issue:5 Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure, Systolic; Humans; Kidney; Male; Middle Aged; Neprilysin; Protease Inhibitors; Registries; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Spain; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left	2021
Combined angiotensin receptor and neprilysin inhibition therapy for heart failure. JAAPA : official journal of the American Academy of Physician Assistants, 2018, Volume: 31, Issue:7 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan	2018
Real-Life Indications to Sacubitril/Valsartan Treatment in Patients With Chronic Systolic Heart Failure. Journal of cardiovascular pharmacology, 2019, Volume: 73, Issue:5 Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Clinical Decision-Making; Drug Combinations; Eligibility Determination; Female; Guideline Adherence; Heart Failure, Systolic; Humans; Male; Middle Aged; Neprilysin; Practice Guidelines as Topic; Protease Inhibitors; Recovery of Function; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left	2019
Real-World Prevalence of Adverse Events After Initiating Sacubitril/Valsartan Compared With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Systolic Heart Failure. Journal of cardiac failure, 2019, Volume: 25, Issue:5 Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cohort Studies; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure, Systolic; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Retrospective Studies; Tetrazoles; Valsartan	2019
[Systolic heart failure. New drug improves prognosis significantly]. MMW Fortschritte der Medizin, 2014, Sep-11, Volume: 156, Issue:15 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Early Termination of Clinical Trials; Enalapril; Heart Failure, Systolic; Humans; Prognosis; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan	2014
Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC medicine, 2015, Feb-18, Volume: 13 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Health Knowledge, Attitudes, Practice; Heart Failure, Systolic; Humans; Male; Middle Aged; Neprilysin; Tetrazoles; Valine; Valsartan	2015
Sacubitril-valsartan and the evolution of heart failure care. Cleveland Clinic journal of medicine, 2015, Volume: 82, Issue:10 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure, Systolic; Humans; Neprilysin; Tetrazoles; Valsartan	2015
[New therapy option ARNI]. MMW Fortschritte der Medizin, 2016, Jun-23, Volume: 158, Issue:12 Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure, Systolic; Humans; Stroke Volume; Tetrazoles; Valsartan	2016